Breakthroughs in Nerve Damage and Spinal Cord Injury Treatments

NervGen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) is making significant strides in the field of nerve damage and spinal cord injury treatments. With a robust leadership team comprising CEO Mike Kelly, CMO Dan Michael, CFO Bill Adams, and consultant Rich Marcari, the company is focused on advancing its flagship drug, NVG-291. Recently, Nervgen received FastTrack designation from the FDA for NVG-291, which facilitates more frequent communication with the FDA and potentially accelerates the development timeline. To bolster its efforts, Nervgen has welcomed two new executive team members: Liz Eart, Senior Vice President of Program Management, and Chuck Olsen, Senior Vice President of Technical Operations. Liz brings extensive experience in drug development and program management, while Chuck's expertise in CMC and technical operations will ensure the seamless transition of NVG-291 from clinical trials to commercial production.

As detailed in a recent YouTube discussion with BioPub, Nervgen's primary focus is on the development of NVG-291 for the treatment of spinal cord injuries. The company is currently conducting a 16-week single-center trial at the prestigious Shirley Ryan AbilityLab in Chicago. This trial aims to evaluate the efficacy of NVG-291 in improving neuronal connectivity and motor function in patients with motor incomplete spinal cord injuries. One of the significant milestones for Nervgen was achieving FastTrack designation for NVG-291. This designation highlights the unmet medical need and the promising preclinical data supporting the drug's potential. The clinical trial population is carefully selected to match the characteristics of animal models, focusing on motor incomplete patients to ensure the best chances of translating preclinical success into human trials.

However, enrollment has been slower than anticipated due to the challenge of finding a homogeneous patient population willing to relocate to Chicago for the trial. CEO Mike Kelly acknowledged the difficulty: "We are trying to make a population that has very little homogeneity as homogeneous as we possibly can," according to the Biopub interview with Biopub. Despite these challenges, Nervgen remains committed to ensuring the trial's success by refining the recruitment process and expanding the search nationwide.

In March, Nervgen raised US$23 million in a bought deal financing, demonstrating strong demand from investors and ensuring the company's financial stability through Q3 2025. This funding will support the ongoing clinical trials, preclinical studies, and the development of new programs, including the anticipated NVG-300. The company is preparing for a potential phase three trial while remaining open to the possibility of fast-track approval based on the strength of the NVG-291 data. Consultant Rich Marcari highlighted the FDA's potential flexibility, emphasizing that regulatory strategies are designed to maximize the chances of expedited approval: "We have experts who are helping us navigate this process that aren't in the company. These are experts who've done this before with other companies," according to the Biopub interview.

Nerve Regeneration Sector

The global nerve repair and regeneration market is experiencing robust growth, driven by a rising prevalence of neurological disorders. According to an article posted on Skyquest, the market size was valued at U$8.2 billion in 2022 and is projected to grow to US$23.05 billion by 2031, at a compound annual growth rate (CAGR) of 12.17%. This growth is fueled by the increasing number of individuals suffering from conditions such as Parkinson's disease, Alzheimer's, and other central nervous system (CNS) disorders, leading to a higher demand for effective treatment options.

The sector benefits from continuous research and development efforts by major companies, resulting in technological advancements that enhance the efficiency of treatments for neurological disorders. These advancements are expected to contribute significantly to the market expansion. Additionally, the availability of multiple therapies for various CNS disorders further enhances the market potential. For instance, therapies using processed nerve allografts have shown promising results in restoring motor and sensory nerve functions in patients with upper extremity nerve impairments. In a study presented at the annual meeting of the American Society for Surgery of the Hand, it was reported that 75% of patients treated with a specific nerve allograft exhibited recovery of motor function, while 85% experienced restored sensory nerve function.

Moreover, increasing awareness among the general population about neurological disorders, along with factors such as environmental influences, lifestyle choices, genetics, nutrition, and physical injuries, has raised the overall understanding of these conditions. This heightened awareness has contributed to the growing demand for nerve repair and regeneration solutions. North America dominates the global market due to its high prevalence of neurological disorders, advanced healthcare infrastructure, and favorable reimbursement policies. Meanwhile, the Asia-Pacific region is experiencing rapid growth, driven by a large population base, increasing incidence of neurological disorders, and government initiatives aimed at improving healthcare infrastructure.

Catalysts

Several critical catalysts are on the horizon for Nervgen, which were addressed in the interview with Biopub. The completion of patient enrollment in the current clinical trial is expected by Q3 2024, with subsequent data analysis potentially leading to an NDA submission. Additionally, the company plans to unveil details about NVG-300 by the end of June 2024, outlining its potential and future development plans. Nervgen's commitment to innovative treatment solutions for nerve damage and spinal cord injuries positions it as a leader in this crucial field. With a dedicated management team, robust financial backing, and a strategic focus on regulatory success, Nervgen is poised to make significant advancements that could transform the lives of patients with spinal cord injuries.

Expert Analysis

As seen on StockInvest.us, the NervGen Pharma Corp. stock price saw a significant gain of 15.75% on Monday, June 10, 2024, rising from US$1.46 to US$1.69. This marks the third consecutive day of gains for the stock, generating excitement about whether it will continue to rise or take a minor break in the upcoming days. On the last trading day, the stock fluctuated by 13.91%, moving from a day low of US$1.51 to a day high of US$1.72. Despite a fall in price on 6 of the last 10 days, the stock is still up by 12.03% over the past two weeks. Notably, the trading volume increased significantly on the last day, with 79,000 shares traded compared to the previous day's 45,000 shares, which is a positive technical sign as higher liquidity reduces general risk.

This positioning often suggests a good selling opportunity for short-term traders, as a reaction back towards the lower part of the trend can be expected. A break above the top trend line at US$1.79 would indicate a slower falling rate and could be the first sign of a trend shift. Given the current short-term trend, the stock is expected to fall by approximately 19.96% over the next three months, with a 90% probability that it will hold a price between US$1.02 and US$1.43 at the end of this period. However, if the stock price remains at current levels or higher, the prediction target will likely start to change positively as the conditions for the current predictions will be broken.

Ownership and Share Structure

According to Reuters, NervGen Pharma Corp. has a total of 69.93 million shares outstanding and a market capitalization of $US119.9 million.

Retail investors hold 76.96% of the company’s shares.

PFP Biosciences Holdings LLC, a strategic investor, holds 18.42% of the company’s shares.

Management and insiders hold 3.95% of the company. Advisor William J. Radvak owns 2.34%, with 1.63 million shares, and Founder Harold Punnett holds 1.61%, with 1.13 million shares.

Institutions own 23.04% of the company.

Important Disclosures:

1. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 

For additional disclosures, please click here.